A drug that may speed platelet recovery after stem cell transplants in kids
NCT ID NCT07003256
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This study explores whether romiplostim, a drug that stimulates platelet production, can safely and effectively help platelet recovery in children with thalassemia who receive a half-matched stem cell transplant. Researchers will track how quickly platelet levels rise, how many platelet transfusions are needed, and any side effects. The study involves 16 children aged 2 to 17 who have already received romiplostim as part of their routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- romiplostim (Nplate), a drug to boost platelet production
- What this could lead to
- If successful, this could point toward a way to speed platelet recovery and reduce bleeding risk after stem cell transplants for children with thalassemia.
- What could go wrong
- This is a small, early observational study with only 16 participants, so results may not apply broadly. The drug may cause side effects like thrombosis or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THALASSEMIA IN CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou, Hainan, 570208, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.